| Q90605619 | Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma |
| Q38378516 | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial |
| Q88810010 | Avelumab: A Review in Metastatic Merkel Cell Carcinoma |
| Q53358653 | Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. |
| Q64993029 | Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US. |
| Q64932128 | Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America. |
| Q51751201 | Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. |
| Q58761272 | Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness |
| Q52715853 | Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. |
| Q89860749 | Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity |
| Q64296587 | Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma |
| Q52642670 | Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. |
| Q92067385 | Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma |
| Q47114351 | Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe |
| Q94585008 | Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection |
| Q55356919 | How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. |
| Q90206301 | Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma |
| Q47584286 | Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma |
| Q57153867 | Immunotherapy for Merkel Cell Carcinoma |
| Q55417167 | Immunotherapy for Merkel cell carcinoma: a turning point in patient care. |
| Q64054812 | Immunotherapy in non-melanoma skin cancer: updates and new perspectives |
| Q42370570 | Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma? |
| Q89976301 | Management Recommendations for Merkel Cell Carcinoma-A Danish Perspective |
| Q54252123 | Merkel Cell Carcinoma: An Update and Immunotherapy. |
| Q64982129 | Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. |
| Q89738686 | Merkel cell carcinoma |
| Q47348356 | Merkel cell carcinoma in the age of immunotherapy: Facts and hopes |
| Q64912954 | Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors? |
| Q92949930 | Mitochondria-Targeted and Resveratrol-Loaded Dual-Function Titanium Disulfide Nanosheets for Photothermal-Triggered Tumor Chemotherapy |
| Q90283161 | Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives |
| Q47344401 | Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma |
| Q52686466 | PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. |
| Q92292072 | Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance |
| Q93338919 | Product review: avelumab, an anti-PD-L1 antibody |
| Q38671851 | Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. |
| Q92953428 | Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma |
| Q64071981 | Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab |
| Q39337780 | Skin Cancers in Organ Transplant Recipients. |
| Q57284514 | Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy |
| Q38738614 | Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma |
| Q92533583 | The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy |
| Q64912392 | Travel burden associated with rare cancers: The example of Merkel cell carcinoma. |
| Q64930981 | Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. |
| Q41667462 | Understanding the influence of patient demographics on disease severity, treatment strategy, and survival outcomes in merkel cell carcinoma: a surveillance, epidemiology, and end-results study |
| Q49166849 | Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial |
| Q49210038 | Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting |
| Q40420515 | Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. |